Clinical improvements at Week 36 sustained to Week 64 with aflibercept 8 mg in macular edema following retinal vein occlusion, with significantly fewer injections compared to aflibercept 2 mg: Results from the QUASAR trial
Purpose: To evaluate the efficacy and safety of aflibercept 8 mg versus 2 mg in patients with treatment-naïve macular edema following retinal vein occlusion (MEfRVO). Methods: QUASAR (NCT05850520) was a 64-week, randomized, double-masked, active-controlled, noninferiority, Phase 3 trial of [for full text, please go to the a.m. URL]
Authors
- Franco Mendolia
- Seenu M. Hariprasad (ORCID: https://orcid.org/0000-0003-0985-9551)
- Varun Chaudhary (ORCID: https://orcid.org/0000-0002-9988-4146)
- Anders Pryds
- Ramin Khoramnia (ORCID: https://orcid.org/0000-0002-6237-7773)
- Tobias Niesen
- Zoran Hasanbasic (ORCID: https://orcid.org/0000-0003-0673-012X)
- Alyson J. Berliner
- Sarah Schlief
- Rose Gilbert
- Sergio Leal
- Andrew Chang
- Motohiro Kamei
- Richard Gale
- Aditya Athanikar
- Youxin Chen
- Fabiana Q. Silva
Institutions
- Aichi Medical University (JP)
- Regeneron (United States) (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- University Hospital Heidelberg (DE)
- University of Chicago (US)
- Bayer (Switzerland) (CH)
- Retina Clinic (BR)
- St. Joseph’s Healthcare Hamilton (CA)
- Bayer (Germany) (DE)
- Hull York Medical School (GB)
- Heidelberg University (US)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2026-06-17
- DOI
- https://doi.org/10.3205/26doc135
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00